webinar register page

Webinar banner
ASBMR Webinar: Bench to Bedside and Back Again: Discontinuing Denosumab
Join Michelle McDonald, Ph.D. and Bente Langdahl, M.D., as they present a basic and clinical perspective on the topic of discontinuing denosumab.

Basic Perspective
Michelle McDonald, Ph.D, will present data from a pre-clinical study modelling Desnoumab withdrawal revealing rapid rises in serum TRAP levels above control levels precedes bone loss. She will also present data from a pre-clinical study showing early intervention with zoledronate in multiple doses is superior in preventing serum TRAP rise and bone loss following Desnoumab withdrawal. Lastly, Dr. McDonald will present intravital imaging studies, which reveal osteoclasts undergo cycles of fission and fusion (recycling), which is elevated during Denosumab withdrawal.

Clinical Perspective
Bente Langdahl, M.D., will present data from the ZOLARMAB study investigating different zoledronate regimens after denosumab discontinuation as well as other clinical intervention and observational trials adding information about how best to manage denosumab discontinuation. She will also discuss the recommendations by the ECTS position statement on denosumab discontinuation.

As a result of this webinar participants will be able to:
1. Demonstrate that a rapid rise in osteoclast activity drives bone loss following Denosumab withdrawal
2. Demonstrate that sequential multiple dose Bisphosphonate therapy may prevent Denosumab withdrawal induced bone loss
3. Outline how the novel concept of osteoclast recycling may provide the mechanism behind bone loss following Desnoumab withdrawal.
4. Demonstrate the rapid increase in p-CTX and bone loss after discontinuation of denosumab in patients with osteoporosis after long-term treatment
5. Demonstrate that subsequent treatment with bisphosphonate may ameliorate the rebound activation of bone resorption and bone loss to some extend
6. Outline how discontinuation of denosumab can be managed in the clinic.

Jun 16, 2021 02:00 PM in Eastern Time (US and Canada)

* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



Michelle McDonald, Ph.D.
@The Garvan Institute of Medical Research
Dr. Michelle McDonald’s research careers spans over 19 years, attaining her PhD in 2008 at The Kids Research Institute, Westmead, she is currently Group Leader of the Bone Microenvironment Group at The Garvan Institute of Medical Research, Sydney, Australia. Through the development of a novel intravital imaging technique her research has allowed, for the first time, visualisation and fate tracking of dormant and actively growing tumour cells within living bone, as well as visualisation of bone cells in real time. This approach has revealed previously unappreciated bone cell dynamics and interactions, thereby advancing our fundamental understanding of osteoclast biology, and uncovering mechanisms behind unexpected clinical responses to anti-resorptive therapies.Michelle regularly perform peer reviews, sits on the editorial board for the Journal of Bone Oncology and Clinical Reviews in Bone and Mineral Research and has also held positions on international scientific committees.
Bente Langhdahl, M.D., Ph.D.
@Aarhus University Hospital
Bente Langdahl is a Professor at Aarhus University and a Consultant at the Department of Endocrinology and Internal Medicine at Aarhus University Hospital, Denmark. Bente Langdahl’s main research interests are the development of new treatments and the long-term management of osteoporosis, identification and investigation of genetic variants that imply increased risk of osteoporotic fractures, osteogenesis imperfecta in adults, the impact of thyroid diseases, HIV and diabetes on bone health. She is co-chair of the International Federation of Musculoskeletal Research Societies and past-president of ECTS.